ID

32070

Beschrijving

Study ID: 103992 Clinical Study ID: 103992 Study Title: Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00139334 https://clinicaltrials.gov/ct2/show/NCT00139334 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis This form is for documentation of height and weight (Visits 3, 5 and 6) and blood sample information (visits 3 and 6). Visit 3 -> Timing: day 45, Age: 12 weeks +/- 1 week. Visit 5 -> Timing: day 75, Age: 16 weeks +/- 1 week. Visit 6 -> Timing: day 105, Age: 20 weeks +/- 1 week.

Link

https://clinicaltrials.gov/ct2/show/NCT00139334

Trefwoorden

Versies (2)

1. 16-10-18 16-10-18 - Sarah Riepenhausen
2. 16-10-18 16-10-18 - Sarah Riepenhausen

Houder van rechten

GlaxoSmithKline

Geüploaded op

16 oktober 2018

DOI

Voor een aanvraag inloggen.

Licentie